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Abstract Hemolytic uremic syndrome (HUS) is the most
common cause of acute renal failure in childhood and the
reason for chronic renal replacement therapy. It leads to
significant morbidity and mortality during the acute phase.
In addition to acute morbidity and mortality, long-term
renal and extrarenal complications can occur in a substan-
tial number of children years after the acute episode of
HUS. The most common infectious agents causing HUS are
enterohemorrhagic Escherichia coli (EHEC)-producing
Shiga toxin (and belonging to the serotype O157:H7) and
several non-O157:H7 serotypes. D+ HUS is an acute
disease characterized by prodromal diarrhea followed by
acute renal failure. The classic clinical features of HUS
include the triad of microangiopathic hemolytic anemia,
thrombocytopenia, and acute renal failure. HUS mortality is
reported to be between 3% and 5%, and death due to HUS
is nearly always associated with severe extrarenal disease,
including severe central nervous system (CNS) involve-
ment. Approximately two thirds of children with HUS
require dialysis therapy, and about one third have milder
renal involvement without the need for dialysis therapy.
General management of acute renal failure includes
appropriate fluid and electrolyte management, antihyper-
tensive therapy if necessary, and initiation of renal
replacement therapy when appropriate. The prognosis of
HUS depends on several contributing factors. In general
“classic” HUS, induced by EHEC, has an overall better
outcome. Totally different is the prognosis in patients with
atypical and particularly recurrent HUS. However, patients
with severe disease should be screened for genetic disorders
of the complement system or other underlying diseases.
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Abbreviations
HUS hemolytic uremic syndrome
VTEC verocytotoxin-producing Escherichia coli
Stx Shiga toxin
EHEC enterohemorrhagic Escherichia coli
FH factor H
FI factor I
CD46 membrane-bound cofactor of the complement
system (MCP)
Definition of hemolytic uremic syndrome
Hemolytic uremic syndrome (HUS) is the primary diagno-
sis for up to 4.5% of children on chronic renal replacement
therapy [1–4]. It is the most common cause of acute renal
failure in childhood. Following the initial description by
Swiss physicians in 1955 [5], the syndrome’s nomenclature
has been discussed intensively. Recently, we published our
suggestions [6]. The European Paediatric Research Study
Group for HUS [1, 6] operates a disease registry for
childhood cases of HUS and encourages comprehensive
investigations upon which to make valid clinicopathologi-
cal and etiological correlations [1, 6–10]. In this review we
focus on HUS associated with enterohemorrhagic Escher-
ichia coli only (Table 1).
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Hemolytic uremic syndrome caused by infections
Introductory comments
HUS caused by infectious agents is a common cause of
acute renal failure in children and leads to significant
morbidity and mortality during the acute phase. In addition
to acute morbidity and mortality, long-term renal and
extrarenal complications can occur in a substantial number
of children years after the acute episode of HUS. The most
common infectious agent causing HUS is enterohemor-
rhagic E. coli (EHEC). Shigella dysenteriae type 1 can also
be associated with HUS, and as described below, HUS
following infections with Streptococcus pneumonia can be
particularly severe and has a higher acute mortality and
higher long-term morbidity compared with HUS caused by
EHEC [11]. D+ or typical HUS was linked to infection with
Shiga-toxin (Stx)-producing E. coli in the early 1980s by
Karmali et al. [7, 8, 12, 13]. Whereas the pathophysiology
of HUS is beginning to be understood, more research needs
to be performed to understand the precise mechanisms of
cell injury in HUS so that specific therapies can be
developed. Importantly, strategies to prevent EHEC infec-
tion and HUS also need to be developed and introduced to
our therapeutic armamentarium.
HUS associated with EHEC
Historical perspective
The original report by Gasser and coworkers described five
fatal patients with hemolytic anemia, renal insufficiency,
and low platelet counts [2, 7]. In these patients, it is not
clear whether a gastrointestinal prodrome was evident.
Almost 30 years later, Karmali et al. [7] found a cause for
this disease. They showed that patients with HUS that was
preceded by diarrhea contained in their stools E. coli strains
that produced a toxin that caused irreversible damage to
cultured vero cells (kidney cells from the African green
monkey). Another working group demonstrated that the
verocytotoxin produced by EHEC strains associated with
HUS is closely related to Stx of Shigella dysenteriae type 1
[8]. Following this description, it was recognized that E.-
coli-producing Stx and, as now known, other putative
virulence factors, are the major causes of pediatric HUS.
Epidemiology
Epidemiologic studies in outbreaks of hemorrhagic colitis
and D+ HUS have clearly shown that some patients develop
hemolytic anemia and/or thrombocytopenia with little
evidence of renal involvement, whereas other children
develop substantial renal disease with normal platelet count
and/or minimal hemolysis [7, 3, 13]. Similarly, EHEC have
been isolated from children with HUS without prodromal
diarrhea, making the distinction of diarrhea-positive HUS
related to infection with EHEC and diarrhea-negative HUS
due to other etiologies less clear.
E. coli O157:H7 is the serotype most commonly
implicated in D+ HUS worldwide. However, several other
non-O157:H7 EHEC serotypes are emerging [13–24].
Gerber et al. [2] described in a prospective study 394
children with HUS from Germany and Austria; 43% of the
stool samples from these patients yielded serotypes others
than O157:H7, including EHEC O26:H11/H− (15%),
sorbitol-fermenting (SF) O157:H− (10%), O145:H28/
H− (9%), O103:H2/H− (3%), and O111:H8/H− (3%). In a
follow-up study from the same region, the proportion of SF
EHEC O157:H− increased to 17% [20]. In this study,
besides HUS patients who excreted EHEC-producing Stx,
an additional 9% of patients shed EHEC that lost Stx genes
during infection (EHEC-LST) [20].
Once a person is infected with an EHEC, the percentage
of patients in whom the infection progresses to HUS
depends on the infecting EHEC serotype and was reported
Table 1 Classification (modified from [6])
Aetiology advanced
1) Infection induced
(a) Shiga and verocytotoxin (Shiga-like toxin)-producing bacteria;
enterohemorrhagic Escherichia coli, Shigella dysenteriae type 1,
Citrobacter
(b) Streptococcus pneumoniae, neuraminidase, and T-antigen exposure
(c) other infectious agents
2) Disorders of complement regulation
(a) Genetic disorders of complement regulation
(b) Acquired disorders of complement regulation, for example anti-FH
antibody
3) von Willebrand proteinase, ADAMTS13 deficiency
(a) Genetic disorders of ADAMTS13
(b) Acquired von Willebrand proteinase deficiency; autoimmune,
drug induced
4) Defective cobalamine metabolism
5) Drug induced (Quinine)
Clinical associations: etiology unknown
1) HIV
2) Malignancy, cancer chemotherapy and ionizing radiation
3) Calcineurin inhibitors and transplantation
4) Pregnancy, HELLP syndrome and oral contraceptive pill
5) Systemic lupus erythematosus and antiphospholipid antibody syndrome
6) Glomerulopathy
7) Familial, not included in part 1
8) Unclassified
FH factor H; HELLP Hemolytic anemia, elevated liver enzymes, and
low platelets; HIV human immunodeficiency virus; HUS hemolytic
uremic syndrome; TTP thrombocytopenia
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for EHEC O157:H7 to be 15% [25]. According to our
observations, the risk of HUS development is higher in
patients infected with SF EHEC O157:H− and lower in
those infected with non-O157 EHEC (Zimmerhackl, un-
published observation). In children younger than 5 years of
age, the percentage that developed hemolytic anemia or
HUS was 12.9% compared with 6.8% and 8% for children
aged 5–9.9 years and older than 10 years of age,
respectively [26].
The use of antimotility agents was also associated with a
higher risk for development of HUS [27]. A recent study
demonstrated that children with hemorrhagic colitis associ-
ated with EHEC who received antibiotic therapy were more
likely to progress to HUS [27]. However, a subsequent
meta-analysis did not support this conclusion [27]. A study
of 29 children who developed HUS found that children who
received intravenous hydration and volume expansion had
less severe HUS and were more likely to have non-
oligoanuric renal failure [28, 29]. Environmental or genetic
factors that might predispose to the progression of EHEC-
associated hemorrhagic colitis to HUS are unknown. It has
been suggested that alterations in the gene for factor H
recently described in patients with atypical HUS may also
be relevant to epidemic diarrhea-positive HUS [30, 31].
Pathophysiology
Stxs, which are produced by EHEC in the intestine and
subsequently absorbed to the blood stream, are the major
virulence factors responsible for the microvascular endothe-
lial injury that underlies the pathophysiology of HUS [2, 31].
Stx structure, receptors, and transport
All members of the Stx family share a conserved A1-B5
subunit structure. They consist of a single subunit (A) of
approximately 32 kDa, which is proteolytically cleaved to
yield a 28-kDa peptide (A1) and a 4-kDa peptide (A2).
Peptide A1 has enzymatic activity, and peptide A2 connects
the A subunit to the pentamer of five identical B subunits.
The B subunit of Stx may contain several binding sites for
its glycosphingolipid receptor Gb3Cer, which is presented
on endothelial cells [2, 33]. After binding to Gb3Cer at the
cell surface, Stx is endocytosed and retrogradely trans-
ported to the Golgi apparatus and the endoplasmic
reticulum. It is then translocated to the cytosol where it
inactivates ribosomes, thereby causing cell death [32]. The
ribosome-inactivating subunit is the A1 chain that pos-
sesses ribosomal ribonucleic acid (rRNA) N-glycosidase
activity. In some cells, Stx is endocytosed mainly by
clathrin-dependent endocytosis [32], although other mech-
anisms also exist [34]. It has been shown that the fatty acid
of Gb3 is important for efficient transport of Stx to Golgi
apparatus. Therefore, the composition of Gb3 may play a
role in the endocytic pathway used. A raft localization of
StxB was recently found to be required for efficient
retrograde transport [35]. Toxicity induced by Stx is
influenced by cytokine release. In particular, tumor necrosis
factor alpha (TNF-α) is able to increase Gb3 receptor
density and thus increase toxicity to endothelial cells [36].
Heterogeneity of Stx
Sequence analysis of stx genes and toxin neutralization
assays in EHEC strains isolated from patients have shown
the existence of two major Stx families, Stx1 and Stx2,
each of which contains the major Stx type and an increasing
number of variants. The Stx1 family at the present time
consists of Stx1, Stx1c [37], and Stx1d [38]. The more
heterogeneous Stx2 family comprises variants designated
Stx2c [39], Stx2c2 [40], Stx2d [41], Stx2dactivatable [41, 42],
Stx2e [43], and Stx2f [44]. Stx2dactivatable differs from all
known Stx types in that it can be activated in its biological
activity by elastase [42, 45], a constituent of the intestinal
mucus that cleaves the last two C-terminal amino acids of
the A2 peptide of the Stx A subunit [46]. A single strain can
possess one or more different stx genes [18, 19, 42, 47].
Stx2 genes can be duplicated as it was recently demon-
strated [48]. Whereas stx1, stx2, stx2c, and stx2dact genes are
usually expressed [18–20, 23, 42, 48], discordance between
the stx genotype and Stx expression in strains harboring
stx2d or stx2e has been demonstrated [49]. The control of
expression in strains producing Stx and those not producing
Stx appears to be at the level of transcription [49]. Thus, the
detection of Stx using antibodies and cell culture assays
might fail in isolates that are poor secretors of Stx.
Association between the Stx type and HUS
The clinical outcome of an infection involving Shiga-toxin-
producing E. coli (STEC) depends mainly on the type of
Stx produced by the infecting strain and the possession of
non-Stx virulence factors. Subtyping of stx genes in large
collections of EHEC strains isolated from clinically well-
defined subjects demonstrated that EHEC producing Stx2,
Stx2c, or Stx2dactivatable were responsible for severe disease
such as hemorrhagic colitis and HUS [18, 37, 42, 50].
E. coli strains producing Stx1c, Stx1d, Stx2d, and Stx2e
were associated with uncomplicated diarrhea and asymp-
tomatic infections [38, 39, 43, 47, 51]. Whereas strains
producing Stx2 and/or Stx2c usually possess the intimin-
encoding eae gene, which is associated with high virulence
[47], strains producing Stx2dactivatable are eae negative [42].
It can be concluded therefore that highly pathogenic EHEC
organisms are usually eae positive but that eae negative
EHEC exist, which can also cause severe disease in
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humans. Presumably, production of a highly toxic agent
activated by mucus in vivo may compensate for the absence
of intimin, the molecule that mediates the intestinal
adhesion of eae-positive EHEC and thus promotes the
efficient transport of Stx from the intestine into the
bloodstream. Because the risk of HUS following infection
with E. coli strains harboring different stx alleles varies,
there is need for rapid and comprehensive subtyping of stx
genes in STEC isolates at an early stage of the illness [42,
47]. This information will aid risk analysis and prediction
of clinical outcome of the infection.
Loss of Stx during infection
Genes encoding Stx are encoded in the genomes of
lambdoid prophages, which are also called Stx-converting
bacteriophages, or Stx-phages [52–54]. Stx is under the
regulation and control of phage genes, and replication of
the prophages will result in an increase in stx gene dosage
[52, 54]. Stx genes are induced in EHEC strains at a very
low level spontaneously. A dramatic replication of the
phage genomes and thus multiplication of stx genes occurs
after exposure of sublethal doses of ultraviolet (UV) light,
mitomycin C, and various antibiotics [55, 56] and other
stimuli such as H2O2 released from neutrophils [57].
Prophage induction also leads to phage-mediated lysis of
the E. coli cell envelope, which seems to be important for
release of Stx, as no specific Stx transporter proteins have
been identified [52–54]. Although phage-mediated lysis
and Stx release seem to represent the same event [53, 54],
other phage-independent mechanisms, such as lysis by
particular colicins, may contribute to Stx release in vivo
[58]. Following induction, Stx phages can infect other
bacteria in vivo and in vitro if these carry a phage receptor
and a free integration site for the phage [52, 59–61].
Therefore, Stx phages are critical for production of Stx, for
Stx release and for the dissemination of stx genes.
Phages also participate in the loss of stx genes. We recently
demonstrated that several EHEC serotypes lost Stx-converting
phages during infection and thus the capability to produce
Stx [22, 60, 61]. These events involve a change in pathotype
of the infecting organism and thus might contribute to an
altered virulence during the course of infection and pose a
diagnostic challenge [20]. This is due to the fact that
procedures that rely on the detection of Stx or stx genes are
routinely used to screen for EHEC in clinical laboratories
and that mostly only a single stool sample, collected late in
the illness, is available for investigation [20].
Histology
In the histology, the arteriolar afferentes—and more rarely,
the arteriolar efferentes—show these variances: swelling of
the endothelial cell, subendothelial deposits of fibrinoids
substances, and thrombosis of the arterioles. In the
glomerulus, swelling of capillary endothelial cells and
capillary dilatation are found. Further deposits of fibrin in
the capillary, including thrombosis and hyalinosis, are
described (Fig. 1). Tubular damage, focal or segmental,
with necrosis and atrophy is of significance for long-term
outcome. Changes of the interstitium are described, but
there value is unclear. The differences in the arterioles and
glomeruli are more significant than the tubulointerstitial
variances [62–66]. From experimental studies with Stx, it
can be concluded that almost all cell types are involved.
Damage to endothelial cells, mesangial cells, tubular cells,
and also the podocyte are known. The role of the individual
compartment is unclear. However, Stx alone is not the only
toxic factor. Lipopolysaccharide can damage renal cells as
well. The ability to injure human microvascular endothelial
cells has been demonstrated for EHEC hemolysin [67],
cytolethal-distending toxin [68, 69] found in EHEC O157:H7
[69], and non-O157 EHEC causing HUS [70]. Moreover, an
enzymatically active form of serine protease EspP, termed
EspPα, that cleaves factor V, is frequently found in the
EHEC serotypes mostly associated with HUS [71]. In
addition, the inflammatory response contributes to kidney
damage [72]. Thus, it seems, that the basic disease is an
endothelial lesion with secondary thrombosis [63, 64, 72–74].
Clinical manifestations of D+ HUS
After an incubation period of 3–8 days, patients develop
watery diarrhea followed by bloody diarrhea accompanied
with abdominal cramps in the majority of cases (Figs. 2
and 3). About 50% of these patients develop nausea and
vomiting. Only 30% have fever. Use of antimotility agents
and antibiotics [75, 76], bloody diarrhea, fever, vomiting,
elevated serum leukocyte count, extremes of age (<5 years)
and female gender have been associated with an increased
risk for HUS following EHEC infection. These symptoms
are followed by the typical hematological and nephrological
alterations. Patients suffer from hemolytic anemia, throm-
bocytopenia, and renal failure. The clinical picture is
marked by increasing anemic pallor and oliguria or anuria.
Furthermore, edema, arterial hypertension, proteinuria, and
hematuria can occur. Other characteristics are fragmented
erythrocytes, acute decay of hemoglobin, massive increase
of lactate dehydrogenase (LDH), low or undetectable levels
of haptoglobin, and thrombocytopenia.
Depending on the renal damage, high renal retention
values and decrease of creatinine clearance can be found
[77]. Whereas the kidney and gastrointestinal tract are the
organs most commonly affected in HUS, evidence of
central nervous system, pancreatic, skeletal, and myocardial
involvement may also be present [65, 66, 78]. Gastrointes-
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tinal involvement with severe colitis can result in trans-
mural necrosis with perforation and/or the later develop-
ment of colonic stricture [66, 78]. Elevation of pancreatic
enzymes is common, and edema of the pancreas, indicative
of pancreatitis, can be detected by ultrasound or computed
tomography (CT) scan [79]. Central nervous system (CNS)
involvement in typical HUS is common and frequently
presents as lethargy, irritability, and seizures, and in more
severe cases, CNS disease presents as paresis, coma, and
cerebral edema. Skeletal muscle involvement manifested as
rhabdomyolysis occurs in rare cases, and fortunately,
myocardial involvement is rare as well [80, 81]. When
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Fig. 2 Development of Shiga-
toxin-associated hemolytic
uremic syndrome (used with
permission from [72])
Fig. 1 Hematoxylin and eosin staining in hemolytic uremic syndrome
(HUS). Note that two glomeruli are completely sclerosed (solid line).
Mesangial expansion with beginning sclerosis in the third glomerulus
(broken line). Focal inflammation in the tubular system indicating
involution of renal parenchyma (arrow). Courtesy of Prof. Dr.
Consolato Sergi
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myocardial involvement occurs, elevated troponin I level may
reflect the degree of myocardial ischemia [81]. HUS mortality
is reported to be between 3% and 5%, and death due to HUS
is nearly always associated with severe extrarenal disease,
including severe CNS disease [66, 76, 82].
Antibiotic treatment and potential preventive agents
There is a long history of the discussion of antibiotic
treatment for EHEC-induced diarrhea. Ever since in vitro
studies demonstrated that EHEC produces more toxins
when stimulated by nonlethal concentrations of antibiotics,
this issue has been under controversial discussion.
During the large EHEC outbreak in Japan in 1996, it was
suggested that treatment with Fosfomycin on day 2 after
disease onset reduced the risk of developing HUS. That
study has several drawbacks. In particular almost all
patients were treated, an unusual recommendation in other
parts of the world. In addition, Fosfomycin is rarely used
for this indication at all outside of Japan. Furthermore,
recent epidemiological studies from St. Louis conducted by
the US Centers for Disease Control indicated that antibiotic
therapy for EHEC enteritis resulted in a significantly higher
risk of developing HUS [83]. This adverse outcome may
reflect the effect of specific antimicrobial agents on phage
induction and subsequent Stx gene expression and tran-
scription or increased Stx release after induced bacteria
lysis [17, 25–27].
Some studies demonstrated a harmful effect of antibiotic
therapy in hemorrhagic colitis. Children with hemorrhagic
colitis associated with EHEC who received antibiotic
therapy were more likely to develop HUS compared with
children who did not receive antibiotic therapy [26, 27, 84].
Other studies have not demonstrated such an association,
and a recent meta analysis concluded that administration of
antibiotics in people infected with EHEC was not associ-
ated with the development of HUS. In in vitro studies, it
has been shown that some antibiotics promote production
and release of Stx from E. coli. Currently, there is no
consensus on the use of antibiotic therapy in children with
hemorrhagic colitis or HUS; however, antibiotics are not
usually prescribed in children with HUS until there are
specific indications for antibiotic therapy. In conclusion,
during the diarrheal phase, antibiotic treatment should be
avoided, as beneficial effects regarding initiation of HUS
cannot be deduced from recent studies [25, 84, 85].
Antibiotic treatment after HUS onset has not been shown
to be of negative influence for long-term outcome (personal
observation, LBZ).
Other preventive strategies
A diatomaceous silicon diamide compound linked to an
oligosaccharide chain (Synsorb® Pk) was developed and
shown to avidly bind and neutralize Stx. A clinical trial was
recently completed to determine whether oral administra-
tion of Synsorb® Pk can decrease the rate of progression of
hemorrhagic colitis to HUS or whether it can decrease the
need for dialysis or extrarenal complications in children
who have developed HUS. Unfortunately, the Synsorb® Pk
was not found to be beneficial in preventing extrarenal
complications or decreasing the duration of dialysis in
children with new-onset HUS. Starfish is a new compound
shown to bind to Stx 1,000 times more efficiently than
Synsorb® Pk. Starfish is a pentameter that binds Stx and
has the potential to be administered intravenously. Starfish
has been shown to protect mice against a lethal dose of
Stx1 but not Stx2, whereas a modified version of Starfish,
called Daisy, protected mice against lethal doses of Stx1
and Stx2 [86, 87].
Stx antibodies
Very interesting results have been obtained from studies
that demonstrated that monoclonal antibodies specific for
the A subunit of Stx2 prevented lethal complications in
mice when administered after diarrhea onset. The authors
suggested that treatment of children with this antibody after
the onset of bloody diarrhea may be protective against HUS
development. Other very interesting recent studies demon-
strated that vaccination with a plant-based oral vaccine
protected mice against a lethal systemic intoxication with
Stx2 [88].
Dialysis
The majority of children with HUS develop some degree of
renal insufficiency. Approximately two thirds of children
with HUS will require dialysis therapy, and about one third
will have milder renal involvement without the need for
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spontaneous resolution
days after EHEC ingestion
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Fig. 3 Pathophysiology of enterohemorrhagic Escherichia coli
infection. Prodromal phase usually 3 days. Window for Shiga toxin
antibody treatment is from day 0 to day 3 after onset of diarrhea.
Sequelae in percent of patients. Adapted and modified from [24]
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dialysis therapy [2]. Peritoneal dialysis and hemodialysis
modes have been used in the past. In most centers,
peritoneal dialysis is the preferential choice. However,
there is no priority to one or the other. We recommend that
hemodialysis may be started if atypical HUS is suggestive.
This is particularly true in older children and those without
clear diarrhea. In younger children, most centers prefer
peritoneal dialysis. It has been argued that PD may have a
higher risk of peritonitis in patients with bloody diarrhea.
However, this has not yet been reported [75].
Thus, HUS management encompasses the usual manage-
ment of children with acute renal failure with additional
management issues specific to HUS. General management
of acute renal failure includes appropriate fluid and
electrolyte management, antihypertensive therapy if the
child demonstrates hypertension, and initiation of renal
replacement therapy when appropriate [76]. Specific man-
agement issues in HUS include managing the hematological
complication of HUS, monitoring for extrarenal involve-
ment in HUS, avoiding antidiarrheal drugs, and possibly
avoiding antibiotic therapy. Managing hematological com-
plications of HUS, including hemolytic anemia and throm-
bocytopenia, should involve frequent laboratory studies to
include a hemoglobin and hematocrit determination on a
frequent schedule, as children may undergo rapid hemolysis.
In addition, jaundice may develop due to the hemolytic
process and is characterized by an increase in indirect
bilirubin. Transfusion with packed red blood cells is needed
when the hemoglobin is falling rapidly and/or when the
hemoglobin reaches 6–7 mg/dl. Children should be trans-
fused with packed red blood cells over a 2- to 4-h interval
with diuretic therapy, as indicated if the child has evidence
of volume overload. Careful monitoring of blood pressure,
urine output, and respiratory status are important to assure
that the child does not develop pulmonary edema.
Thrombocytopenia can be profound, but platelet trans-
fusions are usually limited to the need for a surgical
procedure or in active bleeding. The rationale for limited
platelet transfusions is that they can contribute to the
development of microthrombi and promote tissue ischemia,
with an aggravation of HUS symptoms, in particular,
neurological deterioration. Since microthrombi form during
the course of HUS in multiple organs, including the kidney,
central nervous system, colon, pancreas, skeletal muscle,
myocardium, and other organs, accelerated deposition of
microthrombi may occur following platelet transfusions and
promote tissue injury. Intravascular volume needs to be
considered when a transfusion is indicated, as many
children with acute renal failure due to HUS are oliguric
and at risk for fluid overload and pulmonary edema.
The kidney and gastrointestinal tract are the organs most
commonly affected in HUS, but other organs are also
affected in a substantial number of children. CNS involve-
ment may be manifested as irritability, seizures, and/or
coma. In some patients, pancreatitis with or without glucose
intolerance will develop during the acute phase of the
disease, whereas skeletal and myocardial involvement may
also be present. It is very important to evaluate the presence
and extent of extrarenal involvement, as these complica-
tions of HUS are what contribute to the mortality of HUS.
In children with HUS, physical examination and appropri-
ate laboratory studies are needed to monitor for the
development of extrarenal manifestations. The neurological
examination screens for CNS involvement, and radiograph-
ic imaging is needed in symptomatic patients, including
those with combativeness, irritability, seizures, and de-
creased level of consciousness. In addition to monitoring
the level of renal function, hemoglobin, hemolytic param-
eters (LDH, haptoglobin), hematocrit, and platelet count, as
described above, amylase, lipase, glucose, and liver
function studies should be performed during the acute
phase of the disease.
In children with hemorrhagic colitis due EHEC infec-
tion, the use of antimotility agents has been associated with
a greater risk for developing HUS. Thus, antidiarrheal
agents are usually avoided, as it is thought that this
contributes to retention of Stx within the colon, which
could enhance absorption of the toxin [25, 72, 75, 76, 84].
Plasma therapy
While clearly indicated in some children with atypical
HUS, therapy with plasma infusion [89] and or plasma
exchange [90] has proven to be beneficial in Stx-associated
HUS [89, 90]. In situations where the child is in jeopardy,
in particular with neurological symptoms, plasma exchange
is used. Nevertheless, it should be stressed that there is no
evidence that such procedure is beneficial to the patient
(personal observation, LBZ).
Prognosis: long-term outcome
HUS prognosis depends on several contributing factors. In
general “classic” HUS induced by gastrointestinal bacteria
(EHEC) has an overall better outcome than does atypical
HUS. HUS caused by pneumococci is probably hampered
by more severe active and chronic sequelae. Totally
different is the prognosis in patients with atypical and, in
particular, recurrent disease. In a small study in Europe, the
outcome after 1 year was significantly worse regarding
renal function and increased arterial blood pressure. The
group with EHEC-associated HUS had a normal glomerular
filtration rate (GFR) on average and normal blood pressure,
whereas patients with recurrent disease had a GFR on
average in renal insufficiency grade 3. The same was true
for arterial blood pressure, which was significantly elevated
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in two thirds of patients. The situation after transplantation
seems to be even more difficult. This issue will be
addressed later [10, 88].
As dialysis techniques are available for all age and
weight groups, the prognosis of renal failure in HUS has
improved significantly. Furthermore, improvement in han-
dling these children by pediatric nephrologists has resulted
in better survival. Some children never recover renal
function and require long-term renal replacement therapy,
whereas those who recover are at risk for late development
of renal disease.
HUS is not a kidney disease. In many children, extrarenal
symptoms occur. Neurological symptoms such as seizures
are present in a quarter of patients. Therefore, some children
have residual extrarenal problems, including neurological
defects, insulin-dependent diabetes mellitus (IDDM), pan-
creatic insufficiency, and/or gastrointestinal complications.
Thus, HUS is a disease with substantial acute and chronic
mortality and multisystem morbidity [82, 91, 92].
Several studies have demonstrated that children who
have recovered from the acute episode of HUS are at risk
for long-term complications, including hypertension, renal
insufficiency, end-stage renal failure, and IDDM. One study
found that 39% of 61 children with a history of HUS
demonstrated late complications, including hypertension,
proteinuria, and renal insufficiency during a mean of
9.6 years after the acute episode. The duration of
oligoanuria was found to be the best predictor of late
complications [75, 76, 82]. Other studies have demonstrated
that histological findings of focal and segmental sclerosis
and hyalinosis are observed several years following HUS. In
this study, only a quarter of the children had normal renal
function during long-term follow-up [85]. Kidney biopsies
performed in children with a history of HUS and residual
proteinuria demonstrated that the majority of these children
had global and segmental sclerosis with interstitial fibrosis,
suggesting that they were at risk for later development of
renal insufficiency. In addition, ambulatory blood pressure
monitoring was abnormal in several children with a history
of HUS and normal casual blood pressure. A meta-analysis
demonstrated that death or end-stage renal disease (ESRD)
occurred in 12% of children with diarrhea-associated HUS,
and 25% of survivors demonstrated long-term renal
sequelae [66, 85]. The role of arterial hypertension is
obvious. The likely increased glomerular pressure associat-
ed with hyperfiltration in the regenerative phase of HUS
might render inhibition of the renin-angiotensin system
beneficial. Although no evidence-based information or a
study of this subgroup is available, angiotensin-converting
enzyme (ACE) inhibitors or angiotensin receptor blockers
(ARB) are preferentially used by pediatric nephrologists.
This is the best treatment available based on the patho-
physiological information.
Children with HUS who were discharged without
neurological injury did not have an increased risk for
subclinical problems with learning behavior or attention,
whereas some children who had major neurological
symptoms had evidence of subtle neurological sequelae,
including clumsiness, poor fine-motor coordination, hyper-
activity, and distractibility. Long-term gastrointestinal com-
plications, such as colonic stricture and bilirubin gallstones,
can develop following apparent recovery of HUS. Perma-
nent or transient IDDM occurs in a small percentage of
children with HUS, and children who have transient IDDM
are at risk for later return of IDDM. Interestingly, these
children do not have anti-islet cell antibodies, and the
pathogenesis of their IDDM is not related to immunologic
injury but rather to decreased beta cell function [66, 79].
Renal transplantation
Renal transplantation in “classic” HUS is rare. Recent
reviews support the notion that in classic HUS, a recurrence
of HUS is the absolute exception. Therefore, in patients
with Stx-associated HUS, transplantation can be performed
without increased risk for transplant failure [10, 93].
Accepted treatment of patients with diarrhea-associated HUS
Despite the increased understanding of the pathophysiology
of EHEC-associated HUS, treatment modalities have not
changed over recent decades. It has been demonstrated that
almost all pharmacological interventions are harmful or at
least do not improve acute and long-term outcome.
However, it is of particular importance to identify patients
with a complement disorder. These patients will very likely
benefit from plasma therapy.
Experimental strategies in patients with D+ HUS
There are several therapeutic strategies on the list. They
include immunization against parts of the Stx molecule,
humanized monoclonal antibodies against Stx, as men-
tioned above, and inhibition of TNF-α, cytokines, and
complement factors. Furthermore, the idea of binding the
released Stx in the gut via amorphic compounds is still
under investigation. No patient is currently under clinical
testing. Thus, our armamentarium to cure HUS is still
limited. However, the hope that a better understanding of
this diverse disease group will produce better therapies is
the driving force for intensified research.
Diagnostic proposals in patients with HUS
Diagnostic workup of patients with HUS has been proposed
by a group of European nephrologists organized in the
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European Study Group on Hemolytic Uremic Syndrome
and Related Disorders. According to the suggestions of this
group, the cause of HUS should be determined. It should be
kept in mind that infectious causes may be linked to other
underlying diseases. Thus, even when EHEC association is
likely, the other causes should be considered. A detailed
description with more hints also for atypical HUS is listed
under the home page of the European Society for Paediatric
Nephrology:
http://espn.cardiff.ac.uk/hus_guideline_2005.pdf
Future
Anti-Shiga toxin antibodies Anti-Stx antibodies have been
shown to prevent HUS in animals. There are several
authorized products on the market. In December 2005, the
US Food and Drug Administration (FDA) approved orphan
drug status for two chimeric anti-Stx antibodies (caStx1 and
caStx2, made by Caprion© Pharmaceuticals, Inc) in the
treatment of STEC infections. The antibodies are intended
to neutralize circulating Stx1 and Stx2, thereby treating the
disease and preventing serious complications such as
gastrointestinal disease, bloody diarrhea, destruction of red
blood cells and platelets, and HUS. The product is being
evaluated for preventing HUS in a dose-escalating, phase 1,
US clinical trial of STEC-infected pediatric patients. It was
also recently designated as an orphan drug for this
indication by the European Medicines Evaluation Agency.
The major drawback is that the window for application is
very small. In particular, the diagnosis of EHEC has to be
made within 5 days after inoculation or within 2 days after
initiation of diarrhea, a challenge that cannot be achieved
routinely with current techniques. However, new diagnostic
tools are under development (see also Fig. 3 for window of
Stx-antibody therapy).
Immunization protocols are under investigation. None is
ready for use in the near future. Complement inhibition can
prevent thrombosis in paroxysmal nocturnal hemoglobinuria
(PNH), a disease with a membrane-bound complement-
inhibitor defect [92]. Under the assumption that Stx-
associated HUS may cause damage to renal cells via local
complement activation, inhibition of complement activation
with a C5 antibody maybe beneficial [94].
In conclusion, an improved understanding of the
mechanisms of Stx infections and the pathophysiology of
cell injury in HUS will lead to new therapeutic strategies
for children with HUS to prevent the acute mortality and
the long-term morbidity of HUS in the near future.
Therefore, research is necessary, and international preven-
tive strategies are mandatory.
www.hemolytic-uremic-syndrome.org
www.hus-online.at
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Multiple-choice questions
(Answers appear following the reference list)
1. How many patients with Stx-producing E. coli
infections develop HUS?
A. 100%
B. <1%
C. 5–15%, and it depends on the age of patients
D. 50–60%
E. All patients with Stx1-producing E. coli
2. Which of the following is associated with a poor HUS
prognosis? (more than one answer is possible)
A. Antibiotic therapies
B. CNS involvement
C. Patients <5 years
D. Female patients
3. Stx is proposed to be the noxious agent in HUS. There
are several types of Stx. Which one is not strongly
associated with HUS?
A. Stx2
B. Stx2dactivatable
C. Stx2c
D. Stx1
4. EHEC is defined as having at least three virulence
factors. Which one does not belong to them?
A. Intimin encoded by eae gene
B. EHEC hemolysin
C. Staphylolysin
D. Stx
E. Verocytotoxin
5. For platelet transfusion in HUS, the following state-
ments are correct (one right answer)
A. Transfusion necessary in all patients with platelet
counts <50,000
B. Transfusion necessary only when signs of bleeding
C. Transfusion necessary in all patients with need for
surgery
D. Transfusion necessary if platelet counts <30,000
6. For dialysis in HUS patients, which of the following
statements is correct
A. Hemodialysis is better than PD
B. PD is better than HD
C. Dialysis is necessary in all patients to remove the toxin
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D. HD is the preferred treatment when plasma therapy
is considered
E. Dialysis is necessary if blood urea nitrogen is >50
7. HUS can be prevented by oral application of silica
gel, which binds Stx.
A. True
B. False
8. Which of the following statements is correct?
A. HUS has the same incidence around the world
B. HUS is more common in Argentina than the USA
C. HUS is mainly caused by adenovirus
D. HUS is the disease of the adolescent child
E. HUS can be prevented by immunization
9. Hemolytic anemia in HUS is Coombs positive. This
statement is
A. True
B. False
10. Patients with HUS usually benefit from (one correct
answer)
A. Plasma infusion
B. Plasma exchange
C. Glucose infusion
D. Appropriate fluid balance
E. Steroids
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